What is the best way to increase the INR in an adult on chronic warfarin therapy with a target INR of 2‑3?

Increasing INR in a Patient on Chronic Warfarin Therapy

For an adult on chronic warfarin with a target INR of 2–3, increase the weekly warfarin dose by 10–15% when the INR is subtherapeutic, recheck the INR within 3–7 days, and avoid routine bridging with heparin unless the patient has high-risk features such as a mechanical mitral valve or recent thromboembolism. 1, 2

Dose-Adjustment Algorithm Based on Current INR

INR < 1.5

• Increase the weekly warfarin dose by 15% 1, 2
• For example, if the current dose is 35 mg/week (5 mg daily), the new dose becomes approximately 40 mg/week (alternating 5.5–6 mg daily or 6 mg on 4 days and 5.5 mg on 3 days) 1

INR 1.5–1.9

• Increase the weekly warfarin dose by 10% 1, 2
• Using the same 35 mg/week example, the adjusted dose is approximately 38.5 mg/week (5.5 mg daily) 1

INR 2.0–3.0 (Therapeutic)

• No dose adjustment needed—continue the current regimen 1, 2

Post-Adjustment Monitoring Schedule

• Recheck the INR 3–7 days after any dose change to assess response and prevent overshooting the therapeutic range 2
• Once two consecutive INRs fall within 2.0–3.0, reduce monitoring frequency to weekly for 2–3 weeks, then monthly once stability is confirmed 2
• The American College of Chest Physicians supports extending monitoring intervals up to 12 weeks in patients with consistently stable INRs 2

Bridging Anticoagulation: When Is It Needed?

• Routine bridging with therapeutic-dose LMWH or UFH is NOT recommended for a single subtherapeutic INR in stable patients, as the absolute daily risk of thromboembolism is only 0.3–0.4% 2
• Consider bridging therapy in high-risk patients:
  • Mechanical mitral valve prosthesis 2
  • Mechanical aortic valve with additional risk factors (atrial fibrillation, prior stroke, heart failure, age > 75 years) 2
  • Recent thromboembolic event (within 3 months) 2
  • Multiple mechanical valves 2

Factors That May Lower INR (Investigate Before Adjusting Dose)

• Medication non-adherence—the most common cause of INR variability 2
• Increased dietary vitamin K intake (e.g., more green leafy vegetables, vitamin K supplements) 2
• Drug interactions with enzyme inducers (rifampin, carbamazepine, phenytoin, St. John's wort) 2
• Gastrointestinal malabsorption (diarrhea, vomiting) 2
• Intercurrent illness affecting warfarin metabolism 2

Common Pitfalls to Avoid

• Do not make dose adjustments for a single slightly low INR (e.g., INR 1.9) if prior values were stable—simply recheck in 1–2 weeks 2
• Avoid dose changes exceeding 20% per week, as larger adjustments increase the risk of INR instability and supratherapeutic overshoot 1
• Do not use loading doses to rapidly increase INR in stable outpatients, as this increases the risk of early overanticoagulation without providing faster therapeutic protection 3, 4
• Elderly patients (> 65 years) typically require lower maintenance doses (2–4 mg daily rather than 5 mg) due to increased warfarin sensitivity 2

Alternative Approach: Computer-Assisted Dosing

• Computer-guided dosing algorithms improve INR control compared with manual adjustments, particularly for less experienced providers 2
• These tools incorporate patient-specific factors (age, weight, concomitant medications) to optimize dose titration 2

Special Considerations for High-Risk Patients

• In patients requiring a higher target INR of 2.5–3.5 (e.g., mechanical mitral valves, recurrent embolism despite standard anticoagulation), an INR of 1.6–1.9 represents a more significant deviation, warranting a 15% dose increase rather than 10% 5
• Each day the INR remains subtherapeutic in high-risk mechanical valve patients increases thrombotic risk by approximately 0.03–0.05% 5